FMC Corporation

FMC Corporation shares rallied 15.8% on Thursday after the agricultural chemicals company reported second-quarter earnings that missed revenue expectations and lowered full-year guidance. Revenue fell 17% to $867 million, missing estimates by $30 million, while adjusted earnings per share of $0.26 beat expectations despite a 62% decline from the prior year. Management now forecasts full-year revenue of $3.5 billion to $3.7 billion, down from a prior range of $3.6 billion to $3.8 billion, and adjusted EPS of $1.34 at the midpoint, down from $1.76. The stock's surge came off a deeply depressed valuation, as investors appeared to welcome progress on debt reduction, including a $400 million investment from Tessenderlo Group for a 20% stake, a $200 million upfront payment from Corteva for rimisoxafen technology, and the $252 million sale of its India business to Crystal Crop Protection Limited. These moves support management's goal of paying down $1 billion in debt this year, offering a measure of relief for a company whose shares had fallen over 90% since early 2023.

FMC stock has fallen roughly 88% over three years, yet it passes five of six valuation checks on Simply Wall St's framework, suggesting the stock leans cheap. The company trades at a price-to-sales ratio of about 0.4 times, well below the chemical sector peer average of around 1.3 times and a model-implied fair multiple of about 1.6 times. A planned US$400 million equity investment from Tessenderlo Group and an agreed US$114 million property sale aim to reduce debt and improve financial flexibility. The key question is whether the current discount reflects excessive pessimism or a fair cushion for balance sheet risk, with the stock's next move likely tied to progress on debt reduction, cash generation, and margins.

FMC Corporation shares climbed more than 8% in pre-market trading after Tessenderlo Group agreed to acquire a 20% equity stake for approximately $400 million. Tessenderlo will purchase FMC shares at $13.30 each, giving the Belgian industrial group ownership of roughly one-fifth of the company's outstanding common stock. FMC said the proceeds will allow it to achieve its target of reducing debt by approximately $1 billion, part of a broader set of balance sheet initiatives that also included a $1.2 billion secured high-yield bond offering and the sale of its commercial business in India for $252 million. The agreement concludes the strategic review process launched by FMC in February 2026, with management reaffirming its commitment to remaining an independent business. Completion of the transaction remains subject to customary closing conditions, including regulatory approvals.

The global nematicides market is projected to grow from USD 2.07 billion in 2025 to USD 3.14 billion by 2035, at a compound annual growth rate of 4.27%, according to a report by SNS Insider. Chemical nematicides dominated with a 72.5% share in 2025, while biological nematicides are the fastest-growing segment at a 16.1% CAGR, driven by regulatory restrictions and organic farming expansion. North America held the largest regional share at 38.5% in 2025, with the U.S. market alone valued at USD 0.69 billion and expected to reach USD 1.04 billion by 2035. The Asia-Pacific region is the fastest-growing market, fueled by horticultural export growth in China, India, Vietnam, and Thailand. Key players include BASF SE, Bayer AG, Syngenta AG, Corteva Agriscience, and FMC Corporation.

FMC Corporation has reached a framework agreement to sell its Newark, Delaware property for roughly $114 million in gross proceeds, with plans to use the funds to reduce debt. The transaction is subject to due diligence, closing conditions, and adjustments, and is expected to close in the fourth quarter of 2026. FMC will lease back the facilities it currently operates under a separate agreement and retain ownership of adjacent properties in Maryland. The company's Stine Research Center, the global headquarters for its R&D organization, will continue operating at the Newark site, with scientific infrastructure and core research activities remaining fully intact. FMC noted that leaseback and operational terms are still in preliminary negotiations and there is no guarantee the deal will be completed.

FMC Corporation and Corteva have announced a co-exclusive strategic supply and license agreement to expand access to FMC's rimisoxafen herbicide technology across North and South America. Under the agreement, FMC retains ownership of rimisoxafen and supplies the active ingredient to Corteva, while both companies independently develop and commercialize exclusive premix formulations for corn and soybean markets. Corteva will make an initial prepayment of $200 million for future product supply. Rimisoxafen is recognized as the industry's first dual mode of action herbicide, providing a higher barrier to resistance development. Pending regulatory approvals, the first commercial sales of rimisoxafen-based products are anticipated by the end of the decade.

The global herbicides market is projected to grow from USD 42.33 billion in 2025 to USD 75.09 billion by 2035, at a compound annual growth rate of 5.92 percent, according to a report by SNS Insider. Selective herbicides held a dominant revenue share of about 65.3 percent in 2025, while the non-selective herbicides segment is expected to grow at the fastest rate due to rising adoption in no-tillage agriculture and herbicide-tolerant crop systems. Cereals and grains accounted for approximately 41.8 percent of revenue in 2025, with fruits and vegetables forecast to be the fastest-growing crop type. North America led the global market in 2025, with the United States representing nearly 82.5 percent of regional revenues, and the U.S. market alone is expected to reach USD 19.01 billion by 2035. Europe is anticipated to reach USD 17.34 billion by 2035, with Germany making up about 28.5 percent of European revenues, while Asia Pacific is the fastest-growing region, driven by intensifying production in China and India.